We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Hutchmed (china) Limited | HCM | London | Ordinary Share |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
266.50 | 265.50 | 273.00 | 267.50 | 264.50 |
Industry Sector |
---|
PHARMACEUTICALS & BIOTECHNOLOGY |
Top Posts |
---|
Posted at 28/1/2024 18:23 by 1jat Lauders - I agree with your sentiment but it could be some time in coming… the macro environment is again at play - I read a US congressman has tabled a bill to sanction certain Chinese Biopharma due to links to the China Army….which cannot be helping US investors.I doubt many investors in smaller pharma are actually expecting/wanting them to transition into self supporting larger pharma cos. It is not clear what CKHH position is….they seem to be happy to hold and see the company grow - they dont currently need any cash from their stake, this effectively means HCM is not for sale. If the Vodafone/3 deal goes through CKHH will pocket a couple of Billion and have options to sell out in 2-3 years…. I expect there will be M&A within China biopharma soon…..many companies have cash for a couple of years if fund raising becomes more difficult they will have to be sold…HCM may get to self sustainability before this happens which will put them into a stronger position to buy. |
Posted at 26/1/2024 11:36 by nerdofsteel just think, HK investors who took shares at the IPO have lost two thirds of their moneyChina is now effectively uninvestible and the Chinese Communist Party knows it. The property sector is collapsing and everything else will follow. |
Posted at 24/1/2024 08:02 by nerdofsteel The Company seems to be quite inept when it comes to Investors, particularly individual ones. I have asked many important questions at the AGM and Simon To has always treated me with disdain. They also need to update their pipeline, it's 6 months out of date. |
Posted at 20/12/2023 16:29 by mcmather There appears to have been a bit coverage today as well from a “HK/China Healthcare Analyst”, albeit, I’m not signed up so do not have access to the piece:“Hutchmed China Ltd (13.HK/HCM.US) - A Valuable Option in the Portfolio...Despite market's lackluster response to fruquintinib’s FDA approval, we're optimistic about HUTCHMED’s outlook...We think HUTCHMED is a relatively safe bet for investors as eventual breakeven is drawing near. If based on conservative calculation, market value of about US...” |
Posted at 09/11/2023 07:47 by lauders Perhaps today's Deutsche Bank ADR Virtual Investor presentation will help change the share price direction after the news?HUTCHMED (China) Ltd. (Nasdaq/AIM: HCM | HKEX: 13) 11/09/2023 8:30PM - 9:00PM |
Posted at 13/7/2023 11:27 by nerdofsteel Carlyle on the Board to protect their investment and hopefully provide some level of corporate development advice, something that the company has not always been particularly good at. Our CEO is a scientist, and seems out of his depth when it comes to corporate development and investor relations (a big part of a CEO's role) |
Posted at 13/6/2023 06:37 by nerdofsteel another day another drop in the share price. US Investors pivoting towards tech, anti-china sentiment and geo-politics has killed this. How on earth can the market value this company lower than 8 years ago. |
Posted at 03/6/2023 08:21 by nerdofsteel yes I think you are right - geo-politics and anti-chinese sentiment are playing a major role here but what surprises me is that the NASDAQ listing seems to control London and HK prices. I was expecting and hoping that inclusion in certain chinese indexes and the southbound stock connect program would mean a big influx of chinese investors and that would mean theat the HK listing would become dominant, but that hasn't happened. |
Posted at 10/5/2023 17:41 by nerdofsteel sheer malaise, no interest, low volume, and clearly there will be no decent uplift here for years.....too many people have lost far too much money, and that includes all the institutional investors, some of whom paid $30+ per share.....ouch |
Posted at 18/7/2021 17:09 by nahoon Yet another publication warning US investors about Chinese-listed stocks: (It's from Barrons. I don't like to infringe copyright but can't stand R Murdoch and his role in spreading fake news, so don't feel too bad about the copy and paste.) Anyway, I'm just really glad we're now listed in HK....The giant “caution” Individual investors who still own, or are considering owning, individual shares of U.S.-listed Chinese stocks need to heed this warning. Barron’s has been writing about the challenges that face Chinese companies on multiple fronts: Beijing has steadily intensified the regulatory scrutiny of its largest technology companies, while U.S.-China tensions escalate and prompt investment restrictions and legislation that create further market ramifications. Yes, the case for investing in China is strong, especially over the long run. China’s rapid economic growth is generally appealing, and has led to a burgeoning middle class that has, in turn, allowed many nascent industries to blossom. Plus, many of China’s homegrown technology companies benefit from government investment, and U.S.-China tensions. But as Barron’s wrote earlier this month, the way to navigate this landscape is by hiring a tour guide in the form of a mutual fund or exchange-traded fund manager that can manage growing complexities. Each week makes that case even stronger. Owning individual shares of Chinese companies listed in the U.S.—whether they’re traded over the counter (rather than on a major exchange) or as American Depositary Receipts (ADRs)—could increasingly become a risky proposition. Institutional investors who have the option of owning shares on a Hong Kong or mainland China stock exchange are well on their way to that transition—whi The ADR-heavy Invesco Golden Dragon exchange-traded fund (PGJ) is down 13% in the last three months. The iShares MSCI China (MCHI), which also owns Hong Kong-listed shares, is down 4%, and the iShares MSCI China A-shares (CNYA), which focuses on China-listed companies, is up 7%. The latest cloud looming over U.S.-listed Chinese companies is uncertainty around how U.S. regulators will enforce last year’s Holding Foreign Companies Accountable Act, which requires foreign companies to adhere to U.S. auditing standards in order to trade on U.S. exchanges. The Chinese government has long prevented Chinese companies from providing the necessary information to comply with U.S. auditing requirements. The process toward enforcement is underway; the feedback period for a Public Company Accounting Oversight Board (PCAOB) proposal closes this week, and policy watchers expect a rule to be released soon. A PCAOB spokeswoman declined to comment. The rule will pave the way for the Securities and Exchange Commission to enforce the legislation. Currently there is a three year-window for compliance; the Senate last month passed a bill that would accelerate the timeline to just two years—another indication of the bipartisan support for China measures. Despite policy makers’ urgency, policy watchers note a lot of outstanding questions. There are some 248 Chinese companies listed on U.S. exchanges with a combined market value of more than $2 trillion—so the process of delisting could be messy and painful. “If a delisting is imminent, the stock price is going to plummet and those who control the company can buy out public investors for a bargain, go private, and relist in Asia at a much higher valuation and make a ton of money—at Americans’ expense,” says Jesse Fried, a professor at Harvard Law School who has been researching regulation of Chinese firms trading in the United States. There’s also no precedent for the type of mass delisting that could unwind in a worse-case scenario—a factor that could lead to an elusive compromise between the two nations. “Despite the ongoing, heightened tensions between the U.S. and China, this could be the last salvo bringing both sides back to the table to work out some deal where there will be just enough access to audit personnel and work papers so that the nuclear option is avoided and the PCAOB will be able to meet its core obligations under the Sarbanes-Oxley Act,” says Shas Das, counsel at King & Spalding, who was the PCAOB’s chief negotiator with Chinese regulators between 2011 and 2015. Past negotiations yielded some cooperation and access to audit work papers but not consistently, he adds. Investors would be ill-advised to wait around to see if some compromise materializes, especially as U.S.-China tensions continue to ratchet higher. On Thursday, the Senate passed a bill to ban imported products from China’s Xinjiang region amid allegations of forced-labor practices, and the U.S. has been adding Chinese companies to a blacklist, cutting them off from U.S. investment. Investors got a painful glimpse at the havoc these measures can cause when widely held China Mobile was delisted in January by the New York Stock Exchange, following an executive order from President Donald Trump banning investment in companies the U.S. said had ties to China’s military. Institutional investors were able to convert into Hong Kong-listed shares, but many retail investors have been stuck in limbo—even now, many investors cannot execute a sale at their current broker, and some are being told to seek out foreign brokers. Others have run into dead-ends with no clarity on who to reach out to for assistance, and face being stuck with a loss. The SEC didn’t respond to a request for comment. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions